Jia-Hong Tang

Publications (3)0 Total impact

• Article: [Correlation of Fms-like tyrosine kinase 3 (FLT3) gene expression to FLT3/internal tandem duplication mutation in peripheral blood of acute myeloid leukemia.].

  Bing Xu, Peng-Chang Shi, Xiao-Yan Song, Jia-Hong Tang, Shu-Yun Zhou
  [show abstract] [hide abstract]
  ABSTRACT: Fms-like tyrosine kinase 3 internal tandem duplication (FLT3/ITD) is associated with an unfavorable prognosis in acute myeloid leukemia (AML). However, the role of FLT3 expression as well as its correlation to FLT3/ITD has not sufficiently studied. This study was to evaluate the relationship between FLT3 gene expression and FLT3/ITD mutation in patients with de novo AML. FLT3 gene expression was determined by real-time quantitative polymerase chain reaction (RQ-PCR). FLT3/ITD mutation was detected by PCR in 79 de novo AML patients. FLT3/ITD mutations were found in 22.8% (18/79) patients. FLT3 gene expression (range: 0-7320, median: 312) was detected in 92.4% (73/79) patients, but not in normal controls. Compared to AML patients with low FLT3 expressers and without FLT3/ITD mutation, patients with high FLT3 expressers and FLT3/ITD mutation had a significantly higher white blood count as well as a higher ratio of bone marrow blasts. The positive rate of FLT3/ITD mutation was not correlated to the level of FLT3 expression, and no statistical difference of FLT3 expression was found between AML patients with and without FLT3/ITD mutation. The complete remission (CR) rate of AML patients with FLT3/ITD mutation (58.8%) was significance lower than that of those without FLT3/ITD mutation (82.1%). In AML patients without FLT3/ITD mutation, the CR rate was significantly lower in patients with high FLT3 expressers (69.2%) than in those with low FLT3 expressers (93.3%). The FLT3 expression is not associated with FLT3/ITD mutation. High-FLT3 expression may be a poor prognostic factor for AML patients without FLT3/ITD mutation.
  Ai zheng = Aizheng = Chinese journal of cancer 07/2009; 28(6):632-6.
• Article: [The significance of quantification of MDR1 and WT1 gene expression in acute myeloid leukemia].

  Bing Xu, Xiao-Yan Song, Lin Li, Wen-Juan Xu, Jia-Hong Tang
  [show abstract] [hide abstract]
  ABSTRACT: To study the quantification of MDR1 and WT1 gene expression in patients with de novo acute myeloid leukemia (AML) and to explore the role of these two genes in clinical drug resistance and their correlation with risk stratification. A real time quantitative reverse transcriptase polymerase chain reaction method was established for detecting MDR1 and WT1 gene expression levels in 63 de novo AML patients. The expression of WT1 and MDR1 was significantly higher in de novo AML patients than in normal controls (P < 0.001). WT1 levels were significantly correlated with corresponding levels of MDR1 gene in de novo AML patients (P = 0.004). Expression levels of WT1 and MDR1 gene were not associated with FAB subtype and risk stratification (P > 0.05). AML patients with FLT3-ITD mutations had a significantly higher WT1 expression level as compared to with those without (P < 0.05), on the contrary MDR1 expression was not associated with FLT3-ITD mutations (P > 0.05). Patients with co-expression of high levels of WT1 and MDR1 had a significantly lower complete remission rate after induction therapy than those with low levels (P < 0.05). There is a positive correlation between MDR1 gene expression and WT1 gene expression in AML. Quantification of the two gene expression together is more effective for judgement of prognosis in AML.
  Zhonghua nei ke za zhi [Chinese journal of internal medicine] 04/2008; 47(3):221-4.
• Article: Detection of FLT3 gene and FLT3/ITD mutation by polymerase chain reaction-single-strand conformation polymorphism in patients with acute lymphoblastic leukemia.

  Bing Xu, Lin Li, Jia-hong Tang, Shu-yun Zhou
  [show abstract] [hide abstract]
  ABSTRACT: To analyze Fms-like tyrosine kinase 3 (FLT3) gene and FLT3 internal tandem duplication (ITD) mutation in acute lymphoblastic leukemia (ALL) patients of different immunological subtypes. Polymerase chain reaction-single-strand conformation polymorphism (PCR-SSCP) was used to detect FLT3 gene and FLT3/ITD mutation in 63 ALL cases. Among the 63 ALL cases, FLT3 gene was detected in 41 (61.5%) cases. The positivity rate of FLT3 gene in pre-pre B-lineage ALL, pre-B-ALL, B-lineage ALL and T-lineage ALL cases were 93.3% (14/15), 77.8% (14/18), 41.7% (5/12) and 28.6% (4/14), respectively. The positivity rate of FLT3 gene was significantly higher in pre-pre B-ALL/pre B-ALL subtypes (84.8%) than in B-ALL subtypes (41.7%, P<0.005), and the rate was significantly higher in B-ALL subtypes (73.3%) than in T-ALL subtypes (28.6%, P<0.001). Two cases (3.2%) were found to have FLT3/ITD mutation, which were also positive for myeloid antigen expression and diagnosed as acute mixed-lineage leukemia, showing leukocytosis and high percentage of bone marrow blast cells with poor prognosis. FLT3 gene can be detected in both B-and T-lineage ALL patients, but more frequently in the former. In B-lineage ALL patients, FLT3 gene is more frequent in cases with undifferentiated than those with differentiated blast cells. FLT3/ITD is rarely detected in ALL patients and FLT3/ITD mutation detection might be helpful to identify the genotypes and evaluate the prognosis of acute leukemia.
  Di 1 jun yi da xue xue bao = Academic journal of the first medical college of PLA 11/2005; 25(10):1207-10.